How we helped our client identify where to play and how to win for their hospital product in India
Our client has a hospital care portfolio which is marketed globally. Despite a low per capita use of the product in India, the annual growth rate of usage is among the highest in the world. It was therefore critical for our client to understand which channels they should focus on (where to play) and what points of differentiation would enable them to gain market share in those chosen channels (how to win).
How buyer insights supported the development of an effective market strategy
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.
Men vs women in emerging markets
Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging markets.
While a wide-range range of societal and economic factors influence health outcomes, one of the most significant factors is gender. In addition to overall morbidity and mortality, certain health issues are more commonly associated with one gender. But while biology plays a role, it is predominantly the way in which society structures and shapes men’s and women’s lives that result in health inequalities. Gender norms, roles and expectations vary between cultures, particularly in emerging markets, and affect the way in which health care is accessed. Our latest interactive infographic compares the lives of men vs women in the BRIC emerging markets, and explores how societal factors impact their respective health outcomes.
Nutraceuticals in India: A Challenging Opportunity
Published in eyeforpharma December 2016 by Marc Yates
As growth begins to plateau in more established territories, attention is turning to emerging markets with a fast-expanding middle class. One of these is India. It cannot quite compete with China for sheer volume of potential consumers: China has a population of around 1.38 billion compared with 1.31 billion in India, although the Indian population is expected to catch up by 2022. On the other hand, a significantly larger proportion of the Chinese population lives in urban environments, where factors such as improved access to healthcare, higher disposable income and more exposure to diseases of affluence will create greater demand for nutraceuticals. Nonetheless, India offers considerable potential for growth from a modest base, currently estimated at 1-2% of global nutraceutical sales. To deliver fully on that promise, though, food and pharmaceutical companies need to address a number of regulatory, cultural, economic and structural challenges in the Indian market.